AiCure (H. Code)

by AiCure  · Based in United States → — Pioneers in Verified Medical Adherence. Proven Outcomes. Real-world Evidence.
Internal Medicine Oncology Psychiatry

Regulatory Status Disclosed

Overview

AiCure’s H.Code platform is an advanced AI-powered adherence verification solution designed for pharmaceutical companies, Contract Research Organizations (CROs), and healthcare providers. It leverages cutting-edge computer vision, synchronous chat, and predictive analytics to meticulously monitor and enhance medication and clinical behavior adherence across the entire healthcare lifecycle.

For physicians involved in clinical research, H.Code revolutionizes participant engagement by observing and assisting trial participants directly through their smartphones. This approach not only improves access and participation but also significantly boosts statistical power and deepens the understanding of the intricate relationship between patient behavior and trial outcomes. The platform’s capabilities include eCOA (electronic Clinical Outcome Assessment) and ePRO (electronic Patient-Reported Outcome) capture, allowing for flexible configuration of response visibility for sites and sponsors.

Beyond simple pill counts, AiCure’s system proactively anticipates and manages adherence challenges to prevent participant dropouts. Its responsible AI framework integrates diversity from the outset, aiming to eliminate bias in patient engagement. Clinical teams utilizing H.Code have reported considerable reductions in drop-out rates and enhanced streamlining of their research processes, with proven outcomes such as 92% participant retention and over 1.5 million participant doses captured across thousands of clinical trial sites globally.

Breakthrough research conducted by AiCure demonstrates that medication adherence, as captured by H.Code, serves as a reliable marker for participant retention. Early adherence patterns can predict future early termination risk, allowing for proactive interventions. This technology, combined with AiCure’s central monitoring framework (Clinical Site Services), has been shown to reduce early termination rates for adherent participants to just 7.8% across numerous phase I-IV clinical trials.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered computer vision for adherence verification
  • Synchronous chat for participant assistance
  • Predictive analytics for adherence management
  • eCOA and ePRO capture
  • Proactive adherence management to prevent dropouts
  • Responsible AI for bias elimination
  • Central monitoring framework (Clinical Site Services)
  • Support for 45 languages
  • Global deployment across 46 countries

Use Cases

  • Medication adherence monitoring in clinical trials
  • Improving participant retention in clinical studies
  • Gathering real-world evidence for medication adherence
  • Monitoring clinical behavior adherence
  • Proactive management of adherence challenges
  • Enhancing statistical power in clinical trials

What Physicians Need to Know

Real-World Evidence Analysis
AiCure's H.Code platform is a pioneer in verified medical adherence and proven outcomes, generating real-world evidence. It collects and analyzes behavioral variables, known as digital biomarkers, to understand and predict patient behavior and response to treatment. Data is gathered from real-world settings in various formats including videos, images, audio, and text, which can support safety and efficacy endpoints in clinical trials.
Clinical Trial Management & Adherence
AiCure's H.Code platform enhances clinical trial observation, adherence, and data quality by using AI-powered computer vision, synchronous chat, and predictive analytics. It remotely observes and assists trial participants via smartphones, providing real-time dosing instructions and confirming medication ingestion. The platform helps anticipate and manage adherence proactively to prevent dropouts and can predict patient adherence with high accuracy using as little as 5-14 days of data.
Digital Biomarker Measurement
The platform measures digital biomarkers, including facial and vocal expressivity, to assess conditions like depression and detect subtle changes in a patient's condition. This capability provides novel insights into patient behavior and treatment response.
Collaboration Features
H.Code acts as a bridge between patients and clinical teams, offering dashboards for clinical teams and sponsors with real-time, actionable, and predictive data. It supports communication through secure call, SMS, and video chat, and provides customized support and monitoring for clinical trial sites through AiCure Site Services.
Predictive Analytics for Patient Behavior
AiCure leverages predictive analytics to anticipate participant behaviors and risks during clinical trials, such as non-adherence or early termination. This allows for timely interventions and optimization of patient pools, potentially leading to smaller cohorts and faster trials.
Physician Tip

Physicians can utilize AiCure's platform to gain objective, real-time insights into patient medication adherence and behavioral responses to treatment, which can inform clinical decision-making and improve patient outcomes. The platform's ability to identify non-adherence, including intentional non-adherence, allows for timely interventions and personalized support. Leveraging digital biomarkers can provide a deeper understanding of a patient's condition and treatment impact. The predictive analytics can help identify patients at risk of non-compliance or dropout, enabling proactive engagement and tailored care strategies.

AiCure's H.Code platform is designed to integrate with additional patient data sources, patient companion apps, and existing clinical workflows and records to streamline trial operations. It employs a microservices-driven architecture, utilizing cloud services (such as AWS) to efficiently collect, catalog, and process diverse data modalities including video, audio, image, and text.

Details

Category Drug Discovery & Research, Patient Engagement & Education
Pricing Unknown — unknown
DeploymentTraditional site-based, decentralized, fully virtual, or hybrid models
Mobile AppYes
Data Export Yes
Languages45
Training Yes
Target Sizepharma, CROs, and providers (large enterprises)
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Yes AI-estimated

Ai Cure Technologies adherence solutions registered with FDA under 510K Class 1 Exempt status as a 510K class 1 exempt device.

SOC 2 Yes AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Internal Medicine, Oncology, Psychiatry

Social Proof

Customersunknown
Notable
AbbvieCerevel TherapeuticsSage Therapeutics (mentioned in testimonials)

Support & Reliability

Training Provided Yes

What the Web Says

AiCure's H. Code platform utilizes AI-powered computer vision, synchronous chat, and predictive analytics to monitor patient behavior and enhance medication adherence in clinical trials. It aims to improve data quality, patient outcomes, and streamline the clinical research process for traditional, decentralized, and hybrid trial models. The platform is designed to be a bridge between patients and clinical teams, making trials more accessible and manageable.

Overall: Mixed

Strengths

  • AI-powered adherence verification and patient engagement.
  • Supports various clinical trial models (site-based, decentralized, virtual, hybrid).
  • Provides real-time and predictive insights into trial and site performance.
  • Can reduce early termination rates in clinical trials.
  • Enhances data quality and provides a comprehensive view of therapy impact.
  • Open-source digital biomarker code for increased accessibility and peer-review.

Limitations

  • Mixed employee reviews regarding management, job security, and company culture.
  • Some employees report stress and unproductivity due to leadership issues.
  • Concerns about downsizing occurring frequently.
  • Employees express dissatisfaction with compensation and team quality.
  • Data management can be challenging due to various modalities and decentralized architecture.
  • HR is described as unprofessional and not knowledgeable by some employees.

Based on reviews from: SourceForge, AiCure.com, Indeed, Comparably, Lensa, SoftwareWorld

Last updated: 2026-08-12

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate AiCure (H. Code)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Business Wire
AiCure Bringing New Patient Engagement Platform H.Code to DPHARM 2024
AiCure is set to unveil its H.Code platform at the 14th Annual DPHARMu00ae conference, a new clinical trial technology that integrates computer vision, app-based communication, and predictive analytics to enhance patient engagement and adherence. The company's CEO, Ed Ikeguchi, will also speak on simplifying trial participation with a single platform.
2024-09
Forbes
The AI Company Transforming Medication Adherence And Weight Loss - Forbes
AiCure's H.Code platform uses AI and computer vision to remotely track medication adherence in clinical trials, offering real-time objective data. The company has also launched WeightVerifyu2122 for remote weight monitoring in chronic conditions and was recently acquired by Vive VC.
2026-07
Health AI Central
AI Meets Clinical Trials: Recent Policy Shifts & Companies to Watch
AiCure is highlighted for its H.Code platform, which utilizes computer vision and machine learning for remote patient monitoring in clinical trials, verifying medication adherence and detecting behavioral shifts. The system generates digital biomarkers and uses predictive modeling to identify risks like non-adherence or early dropout.
2025-05
eClinical Forum
eCF Technology Showcase: AiCure: Using AI to improve patient adherence, compliance, and retention - eClinical Forum
AiCure's H.Code platform, described as the world's first patient engagement AI, will be showcased to discuss strategies for improving patient engagement, adherence, compliance, and retention in clinical trials. The presentation will cover simplifying studies by reducing technologies and utilizing predictive analytics.
2025-02
Inside Precision Medicine
Inside Precision Medicine, June 2025 - eMagazines Library
This article highlights AiCure's use of computer vision and machine learning in its H.Code platform to track medication adherence and patient behavior in clinical trials, including facial recognition to verify medication ingestion.
2025-05
PR Newswire
AiCure Appoints Sabina Chadha as CEO, Ed Ikeguchi Transitions to Chief Medical Officer, and Josh Wilson Promoted to COO and President - PR Newswire
AiCure announced leadership changes with Sabina Chadha appointed as CEO, former CEO Ed Ikeguchi transitioning to Chief Medical Officer, and Josh Wilson promoted to COO and President. These changes aim to drive the company's growth and innovation in AI-powered clinical trial solutions.
2025-05
Startup Intros
AiCure: Funding, Team & Investors | Startup Intros
AiCure's H.Code platform is highlighted as an all-in-one AI-driven tool for real-time dosing guidance, eCOA/ePRO, adherence prediction, and predictive analytics for retention risk in clinical trials. The company holds over 84 patents and has a proven impact on reducing early trial terminations.
2026-07
AiCure
AiCurator Empowering Clinical Trial Teams with Self-service Trial Configuration
AiCurator is a new self-service platform that allows clinical trial study teams to independently configure AiCure's H.Code platform, streamlining trial setup, enhancing operational flexibility, and reducing costs and setup times from weeks to days.
unknown

Videos

Product demos, reviews, and walkthroughs for AiCure (H. Code).

View all on YouTube

Frequently Asked Questions

AiCure's H. Code platform utilizes AI-powered computer vision via a smartphone app to visually confirm medication ingestion, ensuring participants take the correct drug at the right time. This real-time monitoring and verification significantly improve medication adherence rates and provide high-fidelity data for clinical trials, reducing variability and strengthening statistical power.
The platform captures objective behavioral data, including visual confirmation of dosing, timing of medication intake, and patient engagement with the app. It also supports eCOA/ePRO capabilities and can identify intentional non-adherence, offering deeper insights into patient response and behavior beyond traditional pill counts.
Key limitations include the requirement for participants to have a smartphone or a provisioned device, and the platform's noted inability to directly export data to all other platforms. Additionally, while it detects non-adherence, the quality and accuracy of the data are contingent on the initial information provided and patient cooperation.
Unlike traditional methods like pill counts or electronic monitoring packaging, AiCure uses AI-powered computer vision for direct ingestion verification, offering a higher level of accuracy and insight into actual drug administration. Compared to other digital solutions, it focuses heavily on objective behavioral data and predictive analytics to anticipate and mitigate adherence risks.
AiCure operates as a regulatory-compliant AI platform designed for clinical trials, implying adherence to relevant data privacy standards. The platform is built to securely collect, catalog, and process video, audio, image, and text data from patients, leveraging cloud services for scalability, flexibility, reliability, auditability, and security.
Yes, AiCure's H. Code platform supports integration with additional data sources, patient companion apps, and clinical workflows to streamline trial operations. This capability allows for a more unified approach to data management within existing clinical research infrastructures.
While specific pricing details are not publicly disclosed, AiCure operates as a B2B platform for pharmaceutical companies, CROs, and clinical sites. Its value proposition includes reducing costs by improving study timelines and mitigating trial failures due to lack of patient oversight, suggesting a service-based or subscription model tailored to trial needs.

Related Tools

MyTrials.ai
MyTrials.ai
Drug Discovery & Research
MyTrials.ai is an AI-powered platform for clinical trial recruitment, combining a verified patient network, intelligent matching, and human navigators to accelerate enrollment.
HypeCheck
2 Minute Medicine
Clinical Decision Support & Reference
HypeCheck™ instantly evaluates health articles, wellness advice, and viral trends by cross-referencing them directly against peer-reviewed literature on PubMed, active clinical trials, and official health agency guidance.
Scite
Scite
Drug Discovery & Research
Scite is an AI research tool that shows how papers have been cited, providing context on whether findings are supported or contradicted by subsequent research, which is valuable for medical writers and researchers.
Google Bard
Google
Clinical Decision Support & Reference
Google Bard, now known as Gemini, is a generative AI model that can assist healthcare professionals with tasks such as summarizing medical records and research papers, generating hypotheses, and providing information on medical conditions.
AIDDISON Explorer
Sigma-Aldrich (Merck KGaA)
Drug Discovery & Research
AIDDISSON Explorer is an AI-powered drug discovery platform combining generative AI with computer-aided drug design for molecular generation, virtual screening, ADMET prediction, and retrosynthesis planning.
Noodle Biomedical Literature Discovery
Helena Bioinformatics
Drug Discovery & Research
Noodle is a biomedical literature discovery platform that allows researchers to search publications by meaning, inspect paper details, and explore related evidence through citation connections and semantic neighborhoods. It offers a public read-only Model Context Protocol (MCP) interface for AI agents.

See all Drug Discovery & Research tools →

Suggest an Edit → | Last Verified: 2026-05-13 | First Added: 2026-05-13

Investors who backed AiCure (H. Code)

Funded through the company that built this tool.

Eurofarma Ventures
Corporate VC T2
Sao Paulo, Brazil
$1M-$5M
Eurofarma Ventures is the corporate venture arm of Eurofarma, one of Latin America’s largest pharmaceutical manufacturers, headquartered in Sao Paulo and deploying…
Biotech Digital Health
BlueRun Ventures Asia
VC T3
Hong Kong, Hong Kong
$1M-$5M
BlueRun Ventures Asia operates from Hong Kong as the Asian extension of the broader BlueRun Ventures platform, applying a long-running consumer and…
Consumer Health Digital Health
Mass General Brigham Ventures
Corporate VC T3
Somerville, United States
$1M-$5M
Mass General Brigham Ventures is a venture fund that creates and backs early-stage life sciences and digital health companies emerging from the…
Biotech Digital Health
TSVC
VC T3
Los Altos, United States
$250k-$1M
TSVC, based in Silicon Valley with a presence at tsvcap.com and an active Crunchbase profile, is an early-stage venture firm best known…
AI/ML in Healthcare Biotech
New Leaf Venture Partners
VC T3
New York, United States
unknown
New Leaf Venture Partners is a long-tenured US healthcare venture firm with a focus on later-stage biopharma and medical device investing, often…
Biotech Diagnostics
Moonfire Ventures
VC T3
London, United Kingdom
unknown
Moonfire Ventures is a London-based early-stage venture firm founded by Mattias Ljungman of Atomico fame, with a thesis built around using data…
AI/ML in Healthcare Digital Health
Flint Capital
VC T3
Boston, United States
$1M-$5M
Flint Capital is a Boston-based venture firm with a transatlantic thesis spanning the US, Europe, and Israel, focused on B2B software, fintech,…
AI/ML in Healthcare Digital Health
AI Tool Finder
AI-powered search. Results may not be comprehensive.